Physician profile
Ali Khan
NPI 1134514227
$3,628.14
in general payments reported to CMS, 2019-2025
27 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.30 · 2022: $230 · 2023: $659 · 2024: $1,237 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,349.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.63 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $438.91 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Boston Scientific Corporation | $401.81 | 2023-2025 | Exalt Model D, Axios, Watchman Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $249.38 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $210.29 | 2023-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $165.14 | 2023-2025 | Sucraid, Sucraid |
| Si-Bone, INC. | $153.75 | 2023 | |
| Phathom Pharmaceuticals, INC. | $151.19 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $144.37 | 2024-2025 | Ibsrela |
| Pfizer INC. | $143.52 | 2025 | |
| Celgene Corporation | $130.32 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $113.76 | 2024-2025 | Dupixent |
| Genzyme Corporation | $88.02 | 2025 | |
| Novo Nordisk INC | $73.99 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $71.95 | 2025 | Iqirvo, Bylvay |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55.47 | 2024-2025 | Zepbound, Omvoh |
| E.R. Squibb & Sons, L.L.C. | $48.30 | 2021 | |
| Alnylam Pharmaceuticals INC. | $44.60 | 2025 | Givlaari |
| Enterra Medical, INC. | $43.01 | 2024 | |
| Vibrant Gastro, INC. | $31.10 | 2024 | Vibrant Starter Kit |
| Gilead Sciences, INC. | $26.72 | 2025 | |
| Echosens North America, INC. | $24.36 | 2024 | Fibroscan |
| Ferring Pharmaceuticals INC. | $24.01 | 2024 | Rebyota |
| Sk Life Science, INC. | $23.68 | 2025 | |
| Digestive Care, INC. | $21.38 | 2025 | Pertzye |
| Capsovision, INC. | $15.04 | 2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $14.44 | 2024 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.